104,121 Shares in Bristol Myers Squibb Company $BMY Bought by TrinityBridge Ltd

Key Points

• TrinityBridge Ltd acquired 104,121 Bristol Myers Squibb shares during the second quarter, valued at approximately $6 million. Institutional investors collectively own 76.41% of BMY, with Vanguard and BlackRock among the largest holders.
• Bristol Myers Squibb exceeded quarterly expectations, reporting $2.04 in earnings per share versus the $1.60 consensus estimate and $12.97 billion in revenue, up 5.7% year over year.
• The company pays a quarterly dividend of $0.63, equivalent to $2.52 annually and a 3.8% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $66.06.

TrinityBridge Ltd acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 104,121 shares of the biopharmaceutical company's stock, valued at approximately $5,998,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares during the last quarter. BlackRock Inc. lifted its stake in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares during the last quarter. State Street Corp boosted its position in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company's stock valued at $5,285,065,000 after buying an additional 1,385,206 shares during the period. Geode Capital Management LLC grew its stake in shares of Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock valued at $2,837,026,000 after buying an additional 6,084,046 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter worth approximately $1,947,272,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Trading Down 3.1%

BMY opened at $65.54 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The stock's fifty day moving average is $60.35 and its two-hundred day moving average is $59.31. The company has a market capitalization of $133.88 billion, a P/E ratio of 14.44, a PEG ratio of 0.18 and a beta of 0.22. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. During the same period in the prior year, the business earned $1.46 EPS. The business's revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. Bristol Myers Squibb's dividend payout ratio is 55.51%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BMY. Roth Capital initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a "buy" rating and a $75.00 price objective for the company. Cantor Fitzgerald reiterated a "neutral" rating and issued a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Sanford C. Bernstein upgraded Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research report on Wednesday, August 5th. BMO Capital Markets reissued a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Finally, Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the stock an "equal weight" rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $66.06.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a collaboration with Chai Discovery to use artificial intelligence for antibody discovery. The partnership could improve the speed and efficiency of developing new therapies, although financial terms and the near-term earnings impact were not disclosed. Chai Discovery collaboration with Bristol Myers Squibb
• Positive Sentiment: An update on the Phase 1 study of navlimetostat indicates continued progress in Bristol Myers Squibb’s early-stage pipeline. The program remains experimental, so any commercial benefit is still distant and uncertain. Bristol Myers Squibb navlimetostat study update
• Positive Sentiment: Hematogenix said its minimal residual disease assay supported the FDA’s accelerated approval of Bristol Myers Squibb’s ZENBEXUS™, described as the first approved CELMoD therapy for multiple myeloma. The approval could expand the company’s oncology opportunity, though accelerated approvals typically require confirmatory evidence. Hematogenix assay and ZENBEXUS approval
• Positive Sentiment: Unusually heavy call-option activity, with 55,757 calls purchased—more than double the average volume—signals increased speculative interest in BMY. Options activity is not confirmation of a sustained rally and can increase volatility.
• Positive Sentiment: Analyst coverage continues to characterize BMY as an attractive value stock, supported by its relatively low valuation and income potential. A separate comparison also frames Bristol Myers Squibb as a potential bargain versus AstraZeneca, though these are opinion-based assessments. Zacks BMY value-stock analysis
• Neutral Sentiment: Articles discussing a covered-call strategy emphasize income generation rather than a bullish outlook for capital appreciation. The strategy may appeal to yield-focused investors but can limit upside if the shares rise sharply. Bristol Myers Squibb options income strategy
• Neutral Sentiment: A report on Aktis Oncology, which has attracted interest from Bristol Myers Squibb and other large pharmaceutical companies, highlights potential future deal activity but does not announce a transaction or create an immediate financial impact for BMY. Pharmaceutical interest in Aktis Oncology

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source